title: A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.
abstract: Cancer is linked to hypercoagulability, and many studies have shown that anticoagulant drugs affect tumor progression. In this study was demonstrated that the Amblyomin-X (which is a recombinant protein that exerts similarity to the Kunitz-type inhibitors and shows pro-apoptotic effects in different tumor cell lines) and heparin (a classic anticoagulant) have similar effects on cancer progression and on normalization of the hypercoagulable state. However, Amblyomin-X showed a distinct mechanism in triggering its effects in vitro, because it exerted a cytotoxic effect in cancer cells by inducing apoptosis and promoting cell cycle arrest.
authors: Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, SP, Brazil.
authors: Janaína Souza
authors: JS
authors: Ventura
authors: Fernanda
authors: F
authors: Faria
authors: Isabel Fátima Correia
authors: IF
authors: Batista
authors: Simone Michaela
authors: SM
authors: Simons
authors: Daniella Gorete Lourenço
authors: DG
authors: Oliveira
authors: Katia L P
authors: KL
authors: Morais
authors: Ana Marisa
authors: AM
authors: Chudzinski-Tavassi
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology*; D060829:Arthropod Proteins; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D018450:Disease Progression; D065427:Factor Xa Inhibitors; D008297:Male; D008546:Melanoma, Experimental / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D012471:Salivary Proteins and Peptides / Q000502:physiology / Q000627:therapeutic use*; D019851:Thrombophilia / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
chemical_list: C559369:Amblyomin-X protein, Amblyomma cajennense; D060829:Arthropod Proteins; D065427:Factor Xa Inhibitors; D012471:Salivary Proteins and Peptides